Trial · NCT01694849
Results by group258
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 258
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 80mg | Efficacy evaluable set / Responders | 21 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 120mg | Efficacy evaluable set / Responders | 19 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Placebo | Efficacy evaluable set / Responders | 16 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 80mg | Efficacy evaluable set / Non-responders | 61 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 120mg | Efficacy evaluable set / Non-responders | 59 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Placebo | Efficacy evaluable set / Non-responders | 61 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 80mg | Full analysis set / Responders | 21 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 120mg | Full analysis set / Responders | 19 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Placebo | Full analysis set / Responders | 16 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 80mg | Full analysis set / Non-responders | 72 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | GFT505 120mg | Full analysis set / Non-responders | 70 | Participants | |
| Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) | Placebo | Full analysis set / Non-responders | 76 | Participants | |
| Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | GFT505 80mg | -0.65 | Standard Deviation 1.33 | NAS score | |
| Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | GFT505 120mg | -0.64 | Standard Deviation 1.68 | NAS score | |
| Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score | Placebo | -0.45 | Standard Deviation 1.34 | NAS score | |
| Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | GFT505 80mg | Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 2 | Participants | |
| Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | GFT505 120mg | Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 2 | Participants | |
| Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | Placebo | Mild (Non-alcoholic Fatty Liver Disease Activity Score 3) | 5 | Participants | |
| Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | GFT505 80mg | Moderate (Non-alcoholic Fatty Liver Disease Activity Score 4-5) | 11 | Participants | |
| Number of Participants With Change From Baseline to Week 52 in Non-alcoholic Fatty Liver Disease Activity Score of at Least 2 Points | GFT505 120mg | Moderate (Non-alcoholic Fatty Liver Disease Activity Score 4-5) | 12 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01694849/results